Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes
https://mct.aacrjournals.org/content/early/2019/08/13/1535-7163.MCT-18-1386
ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors
https://www.thno.org/v10p0151.htm
Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486173/
A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer
http://clincancerres.aacrjournals.org/content/25/1/166
GREB1 amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance
https://elifesciences.org/articles/41913
Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer
https://pubmed.ncbi.nlm.nih.gov/28891793/
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53– and RB1-deficient prostate cancer
https://science.sciencemag.org/content/355/6320/84.full
Abstract B38: Tetravalent bispecific antibodies specific for HER2 and disialoganglioside GD2 to engage polyclonal T cells for osteosarcoma therapy
https://cancerres.aacrjournals.org/content/78/19_Supplement/B38
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction.
A rectal cancer model establishes a platform to study individual responses to chemoradiation
https://www.nature.com/articles/s41591-019-0584-2
A potent tetravalent T-cell–engaging bispecific antibody against CD33 in acute myeloid leukemia
https://www.ncbi.nlm.nih.gov/pubmed/29858209
Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model
https://link.springer.com/article/10.1007/s11307-018-1177-z
Development of a tetravalent anti-GPA33/anti-CD3 bispecific antibody for colorectal cancers
https://europepmc.org/article/PMC/6168351
FOXA1 mutations alter pioneering activity, differentiation, and prostate cancer phenotypes
https://escholarship.org/uc/item/5jq9v28q
Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies
https://stm.sciencemag.org/content/12/534/eaax1315.full
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
https://jhoonline.biomedcentral.com/articles/10.1186/s13045-020-01012-y
Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers
https://www.nature.com/articles/s41467-021-25341-9
Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292228/
Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers
https://www.nature.com/articles/s41467-021-25341-9…
A rectal cancer organoid platform to study individual responses to chemoradiation
https://www.nature.com/articles/s41591-019-0584-2
Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796264/
Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy